Advertisement - Members don't see this ad
"The FDA said it will immediately require boxed warnings about the risk of serious neuropsychiatric symptoms on the packaging of two popular smoking cessation drugs, -- varenicline (Chantix) and bupropion (Zyban, Wellbutrin, and generics).
Reports of behavioral changes, depressed mood, agitation, hostility, and suicidal thoughts and behavior associated with use of the drugs have been submitted to the FDA's adverse event reporting system. "
Srouce: http://www.medpagetoday.com/PublicHealthPolicy/PublicHealth/14931
Reports of behavioral changes, depressed mood, agitation, hostility, and suicidal thoughts and behavior associated with use of the drugs have been submitted to the FDA's adverse event reporting system. "
Srouce: http://www.medpagetoday.com/PublicHealthPolicy/PublicHealth/14931